Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 686.71

+1.7%

10:38 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CuttingEdge Bio who wrote (2868)	3/26/2020 2:47:13 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

< Did you read the full text? Save your accusations.> No, I did not! :-( You did sounded like one, by previous note: Abs do not ENTER CELLS! So, how will nebulizer work? What/how will Abs do absorption? Forced membrane penetration in lungs? For very large molecules (proteins)? Do I need to remand you about those obstacle? Anyway, from China: biorxiv.org <Abstract 31 The pandemic caused by emerging coronavirus SARS-CoV-2 presents a 32 serious global public health emergency in urgent need of prophylactic and 33 therapeutic interventions. SARS-CoV-2 cellular entry depends on binding 34 between the viral Spike protein receptor-binding domain (RBD) and the 35 angiotensin converting enzyme 2 (ACE2) target cell receptor. Here, we report 36 on the isolation and characterization of 206 RBD-specific monoclonal 37 antibodies (mAbs) derived from single B cells of eight SARS-CoV-2 infected 38 individuals. These mAbs come from diverse families of antibody heavy and light 39 chains without apparent enrichment for particular families in the repertoire. In 40 samples from one patient selected for further analyses, we found coexistence 41 of germline and germline divergent clones. Both clone types demonstrated 42 impressive binding and neutralizing activity against pseudovirus and live SARS43 CoV-2. However, the antibody neutralizing potency is determined by 44 competition with ACE2 receptor for RBD binding. Surprisingly, none of the 45 SARS-CoV-2 antibodies nor the infected plasma cross-reacted with RBDs from 46 either SARS-CoV or MERS-CoV although substantial plasma cross-reactivity 47 to the trimeric Spike proteins from SARS-CoV and MERS-CoV was found. 48 These results suggest that antibody response to RBDs is viral species-specific 49 while that cross-recognition target regions outside the RBD. The specificity and 50 neutralizing characteristics of this plasma cross-reactivity requires further 51 investigation. Nevertheless, the diverse and potent neutralizing antibodies 52 identified here are promising candidates for prophylactic and therapeutic 53 SARS-CoV-2 interventions> Any comment?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next